Sponsored Links

Interim Study Data Demonstrate Eligen(R) B12 Oral Formulation Achieves Comparable Results To B12 Injection PDF Print E-mail
Medical News - Complementary and Alternative Medicine
Emisphere Technologies, Inc. (OTC BB:EMIS) announced that interim data from an ongoing study demonstrated its high-dose oral EligenĀ® B12 (1000mcg) performed as well as or better than B12 injections in individuals with Vitamin B12 deficiency...

Read more: Complementary Medicine / Alternative Medicine News From Medical News Today